Market Insight | GIANT BIOGENE surges over 4% again, outstanding performance of Singles' Day flagship products, CanSinoBIO's first day of pre-sale sees a 126% increase in GMV

Giant Biogene rose by over 4%, as of the time of publication, it rose by 4.05% to HKD 56.55, with a turnover of HKD 139 million. On the news front, according to Debon Securities, the sales of collagen components were impressive at the end of the first phase of Double 11 in 2024. Based on data from Li Jiaqi's Tmall live broadcast room, Kemei's first-day presale GMV was approximately HKD 385 million, a year-on-year increase of 126%, accounting for 74% of the total Double 11 period, with growth rate and achievement rate both ranking first among domestic products. Among them, the collagen stick achieved sales of over 500,000 on the first day, with a GMV of HKD 315 million, making it the top-selling domestic product. China Merchants Securities pointed out that Giant Biogene's overall performance in the third quarter met expectations, approaching the guidance given for the second half of the year, and management expressed confidence in achieving the full-year guidance. In addition, this year's Double 11 event period has been extended overall, and preliminary data currently available also show the company's performance to be impressive, with the sales deposit situation of leading influencers meeting expectations